Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (May 2023)
38 slides from Painchek's investor presentation, May 2, 2023
Slide 1: ASX Announcement: Investor Presentation Webinar
ASX ANNOUNCEMENT 2nd May 2023 INVESTOR PRESENTATION WEBINAR TUESDAY 2ND MAY 2023 Further to the webinar announcement on 28th April 2023, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to
Slide 2: Company presentation April 2023
For personal use only Company presentation April 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 3: Our purpose is to give a voice to people who cannot reliably verbalise their pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 4: PainChek Company Highlights
PAINCHEK COMPANY HIGHLIGHTS For personal use only First to market with evidence Multiple large global Regulatory clearance in based technology using AI market opportunities in multiple markets, supported and smart automation hospitals and home care by peer reviewed clinical publications Proven & dom
Slide 5: The Breadth of the PainChek Global Market Opportunity
THE BREADTH OF THE PAINCHEK GLOBAL MARKET OPPORTUNITY For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4. Tsai, I. P
Slide 6: PainChek Well Positioned to Exploit Large Global Market Opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET $300M ANNUAL UP TO 10X AGED 400M PRE- $1B+ ANNUALLY ARR CARE MARKET VERBAL CHILDREN 5
Slide 7: Pain Management Challenges
PAIN MANAGEMENT CHALLENGES For personal use only • Difficulties in assessing Pain Up to • Complex 80% of people in aged • Dynamic care experience • Multidimensional chronic pain1 • Subjective • Education & Training More than • Reporting & Documentation 70% of people in aged care have • Continuous Mo
Slide 8: The Evolution of Pain Assessment
THE EVOLUTION OF PAIN ASSESSMENT Legacy Pain For personal use only PainChek® Assessment Tools “The PainChek app, which I see as a welcome evolutionary development of my past work, was introduced to improve pain management practices by ensuring an evidence-based assessment of pain could be made at th
Slide 9: The PainChek Universal App: Quick and Easy Operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION AI based micro-facial pain expression analysis: For personal use only A medical • 3 second video of patient face device in • recognises 9 micro-facial your pocket expressions indicative of pain Guided Digital questionnaire checklist: • guides the
Slide 10: PainChek Analytics
PAINCHEK ANALYTICS PainChek® Analytics supports your team to draw actionable insights from your PainChek® pain assessment data which helps you realise reduced clinical risk, and ensure pain is identified early, so you can focus on providing care. For personal use only Detailed analytics and reports
Slide 11: PainChek Global Market Strategy
PAINCHEK GLOBAL MARKET STRATEGY For personal use only BUSINESS MODEL TARGET MARKETS/USERS B2B Enterprise: licence • Dementia &/geriatric wards • Hospitals • ER/Post surgical care • Care Homes • Residential & home care providers • Home care Healthcare • Primary Care PainChek Professionals Adult BUSIN
Slide 12: Strong RAC Growth in ANZ & UK Confirm Repeatability & Scalability
STRONG RESIDENTIAL AGED CARE (RAC) COMMERCIAL BEDS GROWTH IN ANZ & UK CONFIRM REPEATABILITY & SCALABILITY Global - ARR $M Global - Annual Licences For personal use only 80,000 $3.50 $3.1 70,000 $3.00 64,163 60,000 55,254 $2.4 $2.50 50,000 $1.9 $2.00 40,308 $1.8 40,000 35,764 $1.50 $1.3 28,288 30,000
Slide 13: On Track to Achieve Core Financial Milestone from Existing RAC Markets
PAINCHEK ON TRACK TO ACHIEVE CORE FINANCIAL MILESTONE FROM EXISTING RAC MARKETS Licences contracted Number (LHS) and ARR $M (RHS) For personal use only 120,000 $4.8 $4.8M 106,000 5.0 100,000 4.0 80,000 $3.1 $3.1M 64,163 3.0 $2.4 60,000 55,254 $1.9 $1.8 2.0 40,308 40,000 $1.3 35,764 28,288 20,000 1.0
Slide 14: Strong Growth in Revenue and Cash Receipts
STRONG GROWTH IN REVENUE AND CASH RECEIPTS Customer recognised revenue by quarter Quarterly Customer (March 2023 Unaudited) - (A$) receipts (A$m) For personal use only $1,800,000 0.70 $1,689,809 $600,000 $1,600,000 $1,419,345 0.60 $500,000 $1,400,000 $1,183,703 0.50 $1,200,000 $400,000 $978,567 $1,0
Slide 15: Consistent Growth in Utility
CONSISTENT GROWTH IN UTILITY Cumulative Number of For personal use only PainChek® Assessments 2,500,000 An increase of 115% over the previous year 2,000,000 and 17% over the prior quarter 1,500,000 Continued strong quarter on quarter growth in clinical utility and implementation progress. 1,000,000
Slide 16: Key Milestones Achieved in the Last Months
KEY MILESTONES ACHIEVED IN THE LAST 12 MONTHS For personal use only 1. 2. 3. Initial RAC market revenues Expand RAC footprint & Infant app market entry to exceed the core Australian enter new markets healthcare professionals & operating costs (eg. Home care, hospital etc) direct-to-consumer REGION G
Slide 17: PainChek in AU – Aged Care's Most Popular Digital Clinical Tool
PAINCHEK IN AU – AGED CARE’s MOST POPULAR DIGITAL CLINICAL TOOL Residential Aged Care For personal use only PainChek® has been widely adopted across Residential Aged Care in Australia, with >60% of the industry having registered to use, or currently using, PainChek. This covers over 1500 separate fa
Slide 18: Integration Partners Provide a Pathway to Accelerated Global Growth
PAINCHEK’S INTEGRATION PARTNERS PROVIDE A PATHWAY TO ACCELERATED GLOBAL GROWTH PainChek integrates and works with aged care management and medication management systems covering more than 180,000 For personal use only aged care beds in Australia, 25,000 beds in New Zealand, 235,000 beds in the UK &
Slide 19: PainChek Enters New Market Sectors in ANZ
PAINCHEK ENTERS NEW MARKET SECTORS IN ANZ For personal use only Maxlife Care Joondalup Health St Louis Aged Care Summerset Group NZ contracted as Campus (Ramsay contracted contracted across all Care Health Care) Centres & fully rolled-out contracted as PainChek’s second PainChek first PainChek’s sec
Slide 20: PainChek Delivering Clinical & Carer Benefits in NZ
PAINCHEK DELIVERING CLINICAL & CARER BENEFITS IN NZ For personal use only “After a successful trial in our Levin village, we are proud to be the first New Zealand aged care provider to implement this innovative tool (PainChek) throughout our villages. PainChek has the ability to capture data directl
Slide 21: UK – 50% Quarterly Growth into the 440,000 Bed Residential Aged Care Market
UK – 50% QUARTERLY GROWTH INTO THE 440,000 BED RESIDENTIAL AGED CARE MARKET For personal use only UK market traction accelerating – Existing South Care group funded New RAC clients in Qtr 15,000 contracted beds (50% by South West London Integrated include Greensleeves growth in Quarter) with 6,000 l
Slide 22: PainChek Outcomes Data
For personal use only PAINCHEK® OUTCOMES DATA
Slide 23: PainChek Helping to Improve Pain Management Outcomes in UK
PAINCHEK HELPING TO IMPROVE PAIN MANAGEMENT OUTCOMES IN UK – PAPER SUBMITTED FOR PUBLICATION Initial outcomes Ongoing outcomes (Year 1) (2 years on) For personal use only • 100% increase in frequency • 10% reduction of of pain assessments antipsychotic drug use (46%stopped use) • 50% increase in num
Slide 24: UK Continuing to Drive Outcomes with New Clients
UK CONTINUING TO DRIVE OUTCOMES WITH NEW CLIENTS UNDERPINNING RAPID GROWTH AND MARKET TAKE UP For personal use only Regular pain monitoring has initiated further investigations: Ability to identify and treat Reduce levels of stress and distress Reduced stress and distress from unreported fractures1
Slide 25: Market Partnership Agreement for USA & Canada Aged Care
MARKET PARTNERSHIP AGREEMENT FOR USA & CANADA AGED CARE For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 PointClickCare is the leading care NORTH AMERICAN AGED CARE management software system provider MARKET OPPORTUNITY to nursing homes in USA & Canada - 1,000,
Slide 26: Market Penetration – Residential Aged Care (RAC)
MARKET PENETRATION – RESIDENTIAL AGED CARE (RAC) Canada For personal use only • Initial RAC sales now in place • Exploring Europe (EU) additional Aged Care and Home • Targeting RAC beds Care partners for and home care North America dementia patients in EU • Exploring International partnerships Japan
Slide 27: PainChek Hospital Market Entry Partnership with InterSystems
For personal use only PAINCHEK® HOSPITAL MARKET ENTRY PARTNERSHIP WITH INTERSYSTEMS
Slide 28: The Challenge of Hospital Based Pain Assessment
THE CHALLENGE OF HOSPITAL BASED PAIN ASSESSMENT For personal use only UP TO UP TO 20% 42% 25-42% of patients impacted of patients impacted by by delirium on delirium during of hospital beds presentation to ED hospitalisation occupied by people with dementia 1. Tsai, I. P., Jeong, S. Y. S., & Hunter,
Slide 29: Consequences of Poorly Managed Pain for Hospitalised Dementia Patients
CONSEQUENCES OF POORLY MANAGED PAIN FOR HOSPITALISED DEMENTIA PATIENTS For personal use only Longer Increased High use of hospital stay delirium risk Antipsychotics 18 3.26 54% days times 1. Germossa et al. BMC Nursing (2019) 18:40 https://doi.org/10.1186/s12912-019-0362-y 2. Tsai, I. P., Jeong, S.
Slide 30: PainChek in Hospital Setting – The Fifth Vital Sign
PAINCHEK IN HOSPITAL SETTING – THE FIFTH VITAL SIGN PainChek and InterSystems have developed a hospital version of PainChek incorporating clinical workflows and full integration within the TrakCare EMR - providing nurses and doctors with the following capability: For personal use only Early warning
Slide 31: InterSystems Partnership - Global Market Access
INTERSYSTEMS PARTNERSHIP - GLOBAL MARKET ACCESS For personal use only 500+ TrakCare sites around the globe CAMBRIDGE, USA World Headquarters Deployed in 27 countries SYDNEY, AU Serving a patient APAC Regional Headquarters population of 100 million+ 30
Slide 32: InterSystems and PainChek Successful Launch at HIMSS Conference
INTERSYSTEMS AND PAINCHEK SUCCCESFULL LAUNCH AT THE HIMMS* CONFERENCE IN CHICAGO PainChek and InterSystems presenting at HIMMS conference Chicago April 17-21 2023 For personal use only and InterSystems Global Summit in Miami June 4-7th 2023 40,000 healthcare professionals, global healthcare companie
Slide 33: PainChek Infant Progress
PAINCHEK INFANT PROGRESS THREE STEP STRATEGY TARGETING MARKET OF 400M PRE-VERBAL CHILDREN Direct to Consumer Marketing • Market testing in progress (completion For personal use only due Q2 CY2023) with parents prior to direct-to-consumer (DTC) market entry • Develop channel partners for DTC market e
Slide 34: Corporate Summary
CORPORATE SUMMARY For personal use only Top shareholders % Financial information Peters Investments Proprietary Ltd 9.14% Share price (20 April 2023) A$0.027 Board & key staff 4.2% Shares on issue 1,298.0m Market capitalisation A$35.0m Cash (31 March 2023) A$3.1m Unlisted options/performance rights
Slide 35: PainChek Upcoming Catalysts
PAINCHEK UPCOMING CATALYSTS For personal use only Continued acceleration of sales and Complete FDA studies to lodge ARR within RAC sector in ANZ, UK, for US FDA De Novo clearance Canada and new EU opportunities in Q4 2023 Enter global hospital market Leverage existing US partnerships sector with Int
Slide 36: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 37: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 38: Philip Daffas, CEO & MD
For personal use only Company presentation April 2023 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 37 |